VorPembro: Vorasidenib and Pembrolizumab in Recurrent or Progressive IDH-1 Astrocytomas

VorPembro: Vorasidenib and Pembrolizumab in Recurrent or Progressive IDH-1 Astrocytomas

Es posible que algunos contenidos no estén disponibles en español.

Study Details

Full Title

CL1-95032-005: A Phase 1, Safety Lead-In and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive IDH-1 Mutant Glioma

Principal Investigator

Katherine
Peters

Protocol Number

PRO00111363

NCT ID

NCT05484622

Phase

I

Enrollment Status

Open to Enrollment
ClinicalTrials.gov